Tuberculosis (TB) is the deadliest infectious disease, and yet accurate diagnostics for the disease are unavailable for many subpopulations. In this study, we investigate the possibility of using human breath for the diagnosis of active TB among TB suspect patients, considering also several risk factors for TB for smokers and those with human immunodeficiency virus (HIV). The analysis of exhaled breath, as an alternative to sputum-dependent tests, has the potential to provide a simple, fast, non-invasive, and readily available diagnostic service that could positively change TB detection. A total of 50 individuals from a clinic in South Africa were included in this pilot study. Human breath has been investigated in the setting of active TB using the thermal desorption-comprehensive two-dimensional gas chromatography–time of flight mass spectrometry methodology and chemometric techniques. From the entire spectrum of volatile metabolites in breath, three machine learning algorithms (support vector machines, partial least squares discriminant analysis, and random forest) to select discriminatory volatile molecules that could potentially be useful for active TB diagnosis were employed. Random forest showed the best overall performance, with sensitivities of 0.82 and 1.00 and specificities of 0.92 and 0.60 in the training and test data respectively. Unsupervised analysis of the compounds implicated by these algorithms suggests that they provide important information to cluster active TB from other patients. These results suggest that developing a non-invasive diagnostic for active TB using patient breath is a potentially rich avenue of research, including among patients with HIV comorbidities.
Respiratory infections caused byPseudomonas aeruginosaandStaphylococcus aureusare the leading cause of morbidity and mortality in cystic fibrosis (CF) patients. The authors aimed to identify volatile biomarkers from bronchoalveolar lavage (BAL) samples that can guide breath biomarker development for pathogen identification. BAL samples (n = 154) from CF patients were analyzed using two-dimensional gas chromatography time-of-flight mass spectrometry. Random Forest was used to select suites of volatiles for identifyingP. aeruginosa-positive andS. aureus-positive samples using multiple infection scenarios and validated using test sets. Using nine volatile molecules, we differentiatedP. aeruginosa-positive (n = 7) fromP. aeruginosa-negative (n = 53) samples with an area under the receiver operating characteristic curve (AUROC) of 0.86 (95% CI 0.71–1.00) and with positive and negative predictive values of 0.67 (95% CI 0.38–0.75) and 0.92 (95% CI 0.88–1.00), respectively. We were also able to discriminateS. aureus-positive (n = 15) fromS. aureus-negative (n = 45) samples with an AUROC of 0.88 (95% CI 0.79-1.00) using eight volatiles and with positive and negative predictive values of 0.86 (95% CI 0.61–0.96) and 0.70 (95% CI 0.61–0.75), respectively. Prospective validation of identified biomarkers as screening tools in patient breath may lead to clinical application.
Infections caused by carbapenem-resistantEnterobacteriaceae(CRE) are alarming in the clinical setting, as CRE isolates often exhibit resistance to most clinically-available antibiotics.Klebsiella pneumoniaecarbapenemase (KPC) is the most common carbapenemase carried by CRE in North America and Europe, frequently detected in isolates ofK.pneumoniae,Escherichia coli, andEnterobacter cloacae. Notably, KPC-expressing strains often arise from clonal lineages, with sequence type 258 (ST258) representing the dominant lineage inK.pneumoniae, ST131 inE.coli, and ST78 and ST171 inE.cloacae. Prior studies have demonstrated that carbapenem-resistantK.pneumoniaediffers from carbapenem-susceptibleK.pneumoniaeat both the transcriptomic and soluble metabolomic levels. In the present study, we sought to determine whether carbapenem-resistant and carbapenem-susceptible isolates ofK.pneumoniae,E.coli, andE.cloacaeproduce distinct volatile metabolic profiles. We were able to identify a volatile metabolic fingerprint that could discriminate between CRE and non-CRE with an area under the receiver operating characteristic curve (AUROC) as high as 0.912. Species-specific AUROCs were as high as 0.988 forK.pneumoniaeand 1.000 forE.cloacae. Paradoxically, curing of KPC-expressing plasmids from a subset ofK.pneumoniaeisolates further accentuated the metabolic differences observed between ST258 and non-ST258.
In this pilot study, volatile molecules produced by cultures of Mycobacterium tuberculosis were evaluated to determine whether they could be used to discriminate between uninfected and M. tuberculosis -infected macaques. Thirty seven of the culture biomarkers were detectable in macaque breath and were shown to discriminate between uninfected and infected animals with an area under the curve (AUC) of 87%. An AUC of 98% was achieved when using the top 38 discriminatory molecules detectable in breath. We report two newly discovered volatile biomarkers, not previously associated with M. tuberculosis, that were selected in both our in vitro and in vivo discriminatory biomarker suites: 4-(1,1-dimethylpropyl)phenol and 4-ethyl-2,2,6,6-tetramethylheptane. Additionally, we report the detection of heptanal, a previously identified M. tuberculosis breath biomarker in humans, as an in vitro culture biomarker that was detected in every macaque breath sample analyzed, though not part of the in vivo discriminatory suite. This pilot study suggests that molecules from the headspace of M. tuberculosis culture show potential to translate as breath biomarkers for macaques infected with the same strain.